sickl
cell
diseas
scd
type
recess
autosom
hemoglobinopathi
caus
specif
mutat
gene
codifi
globin
betachain
hemoglobin
hb
molecul
result
substitut
glutam
acid
valin
posit
chain
thu
creat
hb
hb
polymer
red
blood
cell
caus
alter
shape
hemolysi
caus
acut
event
progress
damag
differ
organ
jame
herrick
first
describ
characterist
shape
red
blood
cell
drepanocyt
sickl
cell
latin
falx
falci
sickl
shape
subsequ
paul
et
al
identifi
electrophoresi
anomali
hb
propos
term
molecular
diseas
thu
demonstr
first
time
product
abnorm
protein
could
caus
genet
disord
sever
genotyp
diseas
caus
differ
clinic
manifest
concept
sickl
cell
anemia
refer
usual
present
patient
inherit
hb
parent
thu
homozygot
diseas
hbss
inher
sgene
anoth
caus
alter
present
sickl
cell
diseas
hbsc
thalassemia
product
chain
partial
product
hb
repres
greatest
proport
hb
erythrocyt
heterozyg
patient
inher
one
allel
parent
allel
normal
hba
name
carrier
hba
known
sickl
cell
trait
carrier
usual
asymptomat
distribut
hb
world
indic
two
factor
migrat
select
individu
hb
carrier
resist
malaria
endem
region
greatest
preval
scd
tropic
africa
estim
everi
year
children
affect
diseas
born
region
live
birth
comparison
children
born
unit
state
europ
migrat
spread
diseas
america
african
popul
also
descend
diagnosi
confirm
hb
analysi
electrophoresi
chromatographi
physiopatholog
manifest
scd
hemolysi
vasoocclus
fig
red
blood
cell
flow
microcircul
hb
deoxygen
caus
involv
chang
composit
molecul
hb
less
solubl
deoxygen
environ
also
caus
stress
hypoxia
acidosi
therefor
hb
polymer
within
red
blood
cell
membran
distort
origin
rigid
cell
poor
deform
hb
polym
trigger
cascad
event
within
cell
activ
transport
channel
potassium
loss
cellular
dehydrationdisrupt
red
blood
cell
membran
thu
expos
membran
compon
band
protein
bind
specif
antibodi
promot
erythrophagocytosi
caus
macrophagesliber
hemoglobin
plasma
promot
oxid
damag
microenviron
vasoocclus
crise
caus
erythrocyt
leukocyt
entrap
microcircul
origin
vascular
obstruct
tissu
ischemia
although
process
requir
hb
polymer
trigger
event
vascular
obstruct
type
inflamm
inflamm
result
interact
erythrocyt
vascular
endothelium
caus
obstruct
ischemia
episod
follow
restitut
vascular
flow
caus
tissu
damag
mediat
reperfus
oxid
stress
trigger
caus
adhes
molecul
overexpress
increas
inflammatori
cytokin
synthesi
leukocytosi
hemolysi
also
contribut
vasoocclus
hemoglobin
liber
plasma
caus
intravascular
hemolysi
gener
superoxid
radic
hydroxyl
potent
inhibitor
nitric
oxid
compound
produc
normal
condit
endothelium
regul
basal
vasodil
tone
inhibit
platelet
hemostat
activ
express
adhes
molecul
depend
nuclear
factor
hb
releas
plasma
also
caus
endotheli
dysfunct
resist
hemolysi
also
liber
erythrocyt
metabol
arginin
ornithin
exhaust
substrat
requir
synthes
help
maintain
hypercoagul
increas
platelet
activ
level
procoagul
factor
blood
import
note
acut
chronic
inflammatori
event
happen
lung
erythrocyt
expos
rel
low
tension
well
slow
flow
cell
airway
vascular
system
close
connect
eas
transfer
inflammatori
mediat
among
scd
consider
phenotyp
heterogen
influenc
genet
environment
factor
hb
fetal
concentr
hbf
coexist
hemoglobinopathi
certain
type
polymorph
simpl
nucleotid
modul
risk
certain
complic
among
environment
factor
environment
humid
cold
pollut
neg
influenc
patient
particularli
increas
vasoocclus
event
complic
worsen
age
infant
dactyl
pain
inflamm
finger
toe
anemia
hyperbilirubinemia
splenomegali
infect
respiratori
tract
common
among
complic
children
may
present
growth
puberti
delay
cognit
alter
cerebrovascular
accid
adult
tend
articular
pain
chronic
ulcer
leg
kidney
failur
neurocognit
disord
sickl
cell
anemia
complic
appear
organ
seriou
chapter
present
pulmonari
complic
tabl
acut
chest
syndrom
ac
symptom
sudden
pulmonari
damag
defin
infiltr
new
consolid
alveoli
chest
xray
evid
atelectasi
involv
least
whole
lung
segment
gener
patient
present
chest
pain
fever
tachypnea
wheez
cough
hypoxemia
cooper
studi
sickl
cell
diseas
csscd
report
incid
episod
patientyear
patient
sickl
cell
anemia
type
ss
almost
half
patient
sickl
cell
anemia
present
one
episod
acut
chest
syndrom
second
caus
hospit
vasoocclus
crisi
voc
may
initi
present
although
also
appear
first
day
case
hospit
stay
children
year
age
greatest
incid
year
per
patient
risk
factor
complic
involv
hbss
thalassemia
asthma
chronic
hypoxemia
low
hbf
tobacco
smoke
exposur
gener
anesthesia
surgeri
mainli
abdomin
winter
season
multipl
caus
ac
nation
acut
chest
syndrom
studi
group
nacssg
studi
caus
episod
present
patient
infect
main
caus
case
thought
respiratori
infect
promot
inflammatori
respons
lung
pneumonia
caus
common
caus
follow
pneumonia
caus
mycoplasma
viral
pneumonia
bacteri
infect
last
anoth
caus
acut
chest
syndrom
fat
embol
bone
ischem
event
piec
marrow
bone
detach
bone
marrow
stroke
migrat
blood
flow
lung
consequ
sudden
inflamm
appear
syndrom
caus
fat
embol
tend
sever
clinic
present
tend
appear
pain
neurolog
symptom
thrombocytopenia
increas
transaminas
activ
secretori
phospholipas
hydrolyz
fat
emboli
posit
creat
free
fat
acid
lysophospholipid
caus
lung
damag
arachidon
acid
caus
hydrolysi
seri
inflamm
mediat
appear
thromboxan
leukotrien
prostaglandin
secretori
phospholipas
increas
ngml
basal
level
ngml
acut
chest
syndrom
present
increas
predict
diseas
within
follow
h
nevertheless
analysi
still
commerci
avail
valid
diagnost
test
third
mechan
ac
pulmonari
stroke
phenomenon
care
studi
could
exclus
diagnosi
recent
observ
patient
may
pulmonari
arteri
thrombosi
etiolog
discov
case
use
multidetector
comput
tomographi
ct
posit
find
studi
mekontso
dessap
et
al
partial
defect
blood
vessel
patient
receiv
anticoagul
treatment
risk
factor
involv
thrombocytosi
less
evid
hemolysi
clinic
present
ac
fluctuat
sever
physician
must
alert
detect
begin
process
typic
clinic
present
character
chest
limb
pain
fever
follow
hypoxemia
dyspnea
sometim
patient
yellow
sputum
probabl
relat
fat
embol
lung
examin
may
reveal
crackl
wheez
reduct
lung
sound
common
find
reduct
hemoglobin
level
gdl
averag
sometim
thrombocytopenia
also
present
thrombocytopenia
independ
risk
factor
suffer
multilob
ac
well
need
assist
ventil
although
patient
treat
without
problem
may
requir
assist
ventil
csscd
investig
report
mortal
children
adult
studi
report
rate
almost
adult
episod
vasoocclus
crisi
recommend
constantli
monitor
oximetri
patient
develop
hypoxemia
oximetri
auscult
symptom
sign
compat
acut
chest
syndrom
appear
chest
xray
requir
diagnosi
confirm
find
new
consolidationin
chest
xray
consolid
common
lower
medial
lung
field
fig
may
pleural
effus
usual
steril
infiltr
long
live
usual
continu
day
especi
infect
involv
computer
tomographi
give
better
view
hyperfus
reduc
number
arteriol
venul
area
ground
glass
present
recommend
repeat
hemogram
diagnos
anemia
thrombocytopenia
well
obtain
cross
histocompat
test
case
transfus
need
obtain
gasometr
analysi
use
treatment
particularli
patient
present
case
respiratori
distress
fever
present
blood
cultur
requir
identifi
bacteri
agent
reduc
number
patient
follow
routin
test
sputum
cultur
ddimer
exam
computer
tomographi
bronchoscopi
necessari
diagnosi
recommend
nevertheless
special
case
patient
condit
worsen
consider
spite
treatment
could
help
find
caus
plastic
bronchiti
complic
consist
mucu
blockag
caus
bronchial
secret
worsen
hypoxem
state
lung
condens
case
procedur
improv
patient
condit
clinic
radiograph
secret
blockag
remov
salin
wash
continu
suction
blockag
attach
tip
bronchoscop
bronchoscop
remov
blockag
airway
attach
figur
summar
algorithm
diagnosi
manag
ac
one
import
measur
avoid
syndrom
direct
spirometri
maximum
inspir
everi
h
patient
awak
small
children
know
use
equip
may
blow
soap
bubbl
anoth
import
measur
adequ
manag
pain
without
oversed
mainten
hydrat
import
vasoocclus
process
patient
scd
concentr
urin
correctli
tend
dehydr
nevertheless
excess
liquid
avoid
promot
lung
edema
combin
iv
cephalosporin
cefuroxim
macrolid
oral
azithromycin
standard
care
altern
regim
case
allergi
quinolon
macrolid
betalactam
antibiot
recommend
oxygen
must
suppli
keep
satur
blood
transfus
must
surpass
maximum
hb
gdl
avoid
increas
viscos
precaut
may
prevent
ac
worsen
recommend
sever
anemia
persist
hypoxemia
transfus
red
blood
cell
must
neg
blood
replac
recommend
case
initi
hemoglobin
high
hb
gdl
patient
requir
transfus
indic
blood
replac
sever
hypoxemia
spite
oxygen
therapi
patient
need
artifici
respir
multilob
ac
also
improv
simpl
transfus
echocardiographi
recommend
patient
need
intens
care
detect
lung
hypertens
case
patient
must
receiv
intens
treatment
blood
replac
airway
hyperreact
scd
investig
propos
routin
use
bronchodil
although
other
use
treat
wheez
prolong
expir
use
steroid
iv
dexamethason
mgkg
everi
h
four
dose
may
shorten
hospit
time
associ
relaps
patient
treatment
interrupt
therefor
use
controversi
although
seem
relat
patholog
hemolysi
well
improv
ac
preliminari
trial
reduc
durat
vasoocclus
crisi
therefor
impact
develop
syndrom
clinic
trial
done
afterward
ac
morbid
wide
short
long
term
syndrom
may
condit
develop
chronic
lung
diseas
acut
lung
hypertens
episod
special
adult
respiratori
failur
nacssg
patient
wide
lobal
affect
platelet
histori
heart
diseas
independ
prognosi
factor
respiratori
failur
difficult
case
respiratori
failur
respond
convent
treatment
highfrequ
oscil
extracorpor
membran
oxygen
ecmo
use
neurolog
event
complic
ac
appear
patient
common
event
alter
mental
state
convuls
neuromuscular
abnorm
platelet
count
risk
factor
neurolog
complic
preval
acut
kidney
damag
increas
sever
chest
syndrom
patient
syndrom
may
develop
multipl
organ
failur
hydroxyurea
drug
capac
increas
hbf
chronic
regim
monthli
transfus
could
reduc
recurr
sever
episod
patient
continu
experienc
episod
even
treat
hydroxyurea
transfus
candid
bone
marrow
transplant
especi
histocompat
sibl
spirometri
lung
volum
diffus
capac
transfer
factor
lung
carbon
monoxid
dlco
correct
hemoglobin
reactiv
measur
revers
airway
bronchodil
routin
lung
function
test
patient
scd
methacholin
parasympathet
agonist
challeng
test
done
routin
low
risk
induc
vasoconstrict
vasoocclus
patient
suffer
lung
dysfunct
tabl
childhood
obstruct
ventilatori
dysfunct
may
appear
case
restrict
ventilatori
dysfunct
may
appear
wedderburn
studi
includ
children
sca
year
old
conclud
function
residu
capac
frc
forc
expiratori
volum
vital
forc
capac
vfc
peak
expiratori
flow
pef
lower
comparison
healthi
children
proport
differ
persist
receiv
bronchodil
suggest
mild
restrict
diseas
year
age
patient
restrict
obstruct
alter
children
sickl
cell
anemia
may
lose
total
capac
per
year
besid
patient
sca
reduc
percentag
peak
expiratori
pressur
pep
comparison
peak
inspiratori
pressur
pip
invers
proport
normal
adult
children
pep
defici
may
contribut
reduct
lung
volum
well
atelectasi
chang
expiratori
muscl
forc
caus
fact
abdomin
intern
intercost
muscl
suppli
epigastr
intercost
arteri
extens
collater
contrari
diaphragm
contribut
inspir
suppli
sever
arteri
therefor
resist
ischem
process
patient
age
lung
function
worsen
adult
sickl
cell
diseas
normal
lung
examin
accord
csscd
analysi
conduct
gener
use
hydroxyurea
gener
adult
patient
show
reduc
lung
caviti
averag
relationship
expect
valu
restrict
pattern
dlco
adjust
expect
valu
hemoglobin
spirometri
within
normal
fvc
valu
expect
respect
therefor
yearli
evalu
lung
function
children
cooper
adult
import
detect
chang
exam
must
preferenti
done
patient
stabl
least
week
pain
episod
although
hydroxyurea
reduc
number
ac
event
adult
children
current
enough
inform
know
modifi
chang
lung
function
studi
babi
hug
follow
ii
sponsor
nation
institut
health
unit
state
evalu
drug
preserv
lung
function
year
comparison
children
receiv
hydroxyurea
airway
hyperreact
measur
bronchodil
use
subfreez
air
hyperventil
common
children
scd
control
patient
particularli
younger
children
preval
hyperreact
may
high
children
scd
asthma
scd
patient
without
asthma
hyperreact
detect
methacholin
patient
scd
comparison
children
gener
popul
comparison
valdivia
et
al
point
preval
asthma
wheez
last
month
studi
chilean
schoolchildren
unit
state
children
ss
hemoglobin
follow
part
multicentr
observ
studi
csscd
bronchial
asthma
preval
similar
asthma
preval
among
afroamerican
import
point
asthma
patient
two
four
fold
risk
develop
acut
chest
syndrom
hospit
vasoocclus
crisi
well
long
hospit
readmit
day
discharg
also
asthma
associ
doubl
death
risk
among
patient
scd
clear
asthma
may
complic
scd
explan
may
lie
common
mechan
leukotrien
leukotrien
lipid
deriv
arachidon
acid
mediat
inflamm
phospholipas
releas
arachidon
acid
cellular
membran
caus
product
leukotrien
leukotrien
produc
process
involv
activ
chemiotaxi
neutrophil
cystein
leukotrien
caus
bronchoconstrict
smooth
muscl
prolifer
mucu
product
airway
edema
may
associ
pain
pathogeni
clinic
record
must
includ
question
onset
respiratori
distress
wheez
exercis
intoler
famili
histori
asthma
patient
evalu
time
questionnair
detect
asthma
control
environment
factor
possibl
condit
gastroesophag
reflux
sinus
obstruct
sleep
apnea
must
consid
patient
asthma
scd
must
treat
follow
recommend
asthma
diagnosi
treatment
summar
group
expert
nation
institut
health
nih
unit
state
also
avail
internet
although
evid
system
steroid
may
exacerb
vasoocclus
crisi
benefit
asthma
control
exce
risk
therefor
inhal
system
steroid
administ
need
agonist
need
may
necessari
electrocardiogram
evalu
qtc
interv
agonist
may
increas
morbid
patient
prolong
qtc
hypoxemia
defin
hemoglobin
satur
oximetri
hemoglobin
desatur
sickl
cell
anemia
part
caus
movement
right
hemoglobin
dissoci
curv
due
hb
properti
effect
chronic
anemia
biphosphoglycer
retrospect
analysi
report
quinn
involv
children
year
old
averag
age
year
old
found
patient
ss
thalassemia
averag
puls
oximetri
satur
sat
present
satur
present
satur
compar
patient
hbsc
thalassemia
averag
satur
satur
level
good
satur
correl
higher
hb
reticulocyt
count
lower
age
patient
recommend
control
satur
followup
patient
also
import
check
patient
receiv
iv
opioid
pain
exacerb
prevent
prolong
hypoxemia
oxygen
administr
hypoxem
patient
sickl
cell
diseas
safe
treatment
increas
anemia
snore
preval
sleep
tend
increas
patient
sickl
cell
diseas
happen
sleep
obstruct
apnea
increas
lymphat
tissu
amygdal
adenoid
retropharyng
node
may
increas
function
asplenia
time
apneahypopnea
night
hypoxemia
relat
priapism
pain
exacerb
cerebrovascular
event
clinic
histori
must
includ
question
sleep
disord
suspicion
polysomnographi
must
request
obstruct
sleep
apnea
treat
amygdalotomi
adenoidectomi
hyperplasia
structur
resist
case
oxygen
administ
without
bipap
machin
patient
sickl
cell
diseas
free
suffer
venou
thrombosi
lung
embol
anemia
procoagul
condit
ad
bedridden
condit
pain
exacerb
risk
increas
doppler
ultrasound
test
limb
chest
helicoid
computer
tomographi
use
detect
lung
embol
manag
complic
type
patient
although
advanc
chronic
pulmonari
diseas
rare
children
sickl
cell
diseas
diseas
relat
acut
recurr
event
vascular
etiolog
acut
chest
syndrom
lung
edema
chronic
fibrosi
fibrosi
observ
mainli
base
lung
detect
highresolut
tomographi
chest
xray
chronic
lung
diseas
tend
progress
worsen
hypoxemia
dyspnea
reduc
paramet
lung
function
patient
correct
dlco
hb
sever
lung
diseas
sometim
differ
level
chronic
lung
diseas
referenc
sickl
cell
anemia
tabl
lung
hypertens
defin
media
lung
arteri
pressur
mpap
mm
hg
determin
heart
catheter
respons
death
adult
ss
thought
lung
hypertens
caus
hemolysi
reduct
discuss
physiopatholog
section
oppos
vasoact
factor
regul
lung
vascular
tone
plasminogen
activ
increas
effect
hypoxiainduc
factor
subunit
endotheli
cell
lung
microvasculatur
time
produc
placent
growth
factor
proangiogen
factor
produc
sickl
cell
plasma
hemin
may
also
contribut
activ
immun
system
inflamm
clinic
factor
contribut
chronic
lung
diseas
hypercoagul
condit
sickl
cell
anemia
low
level
c
protein
previou
histori
splenectomi
american
colleg
cardiolog
foundat
american
heart
associ
recommend
yearli
evalu
patient
risk
develop
lung
hypertens
patient
sickl
cell
anemia
echocardiogram
may
use
test
advers
prognost
tricuspid
regurgit
rate
trr
ms
valu
two
standard
deviat
median
time
trr
use
calcul
mpap
mpap
estim
use
modifi
bernoulli
equat
mpap
spap
systol
pressur
lung
arteri
estim
formula
spap
trr
kanter
krusejarr
right
atrium
pressur
trr
preval
ms
present
children
adult
trr
ms
lung
hypertens
catheter
besid
echocardiographi
evalu
ntermin
probtyp
natriuret
peptid
ntprobnp
walk
test
use
cathet
step
diagnost
process
fig
lung
hypertens
arteri
venou
mix
patient
lung
hypertens
arteri
present
mpap
mm
hg
lung
capillari
pressur
pcp
mm
hg
mean
vasculopathi
mainli
locat
arteri
lung
system
patient
venouslung
hypertens
mpap
mm
hg
besid
diastol
final
pressur
left
ventricl
mm
hg
evid
diastol
failur
transpulmonari
pressur
gradient
mm
hg
lung
hypertens
venou
mm
hg
mix
lung
hypertens
therapi
scd
divid
therapi
aim
anemia
hydroxyurea
blood
transfus
keep
hb
rel
therapi
direct
lung
hypertens
walk
phasst
doubleblind
clinic
studi
treatment
progress
pulmonari
hypertens
sickl
cell
anemia
sildenafil
treatment
design
treat
patient
tricuspid
regurgit
rate
ms
sildenafil
particip
year
old
adult
unfortun
studi
end
earli
advers
event
report
patient
treat
sildenafil
twofold
increas
particularli
relationship
pain
comparison
receiv
placebo
differ
effici
found
anoth
altern
lung
hypertens
use
receptor
antagonist
bosentan
ambrisetan
nevertheless
doubleblind
studi
studi
bosentan
patient
sickl
cell
anemia
lung
hypertens
close
lack
enrol
therefor
inform
drug
relat
patient
limit
patient
system
arteri
hypertens
diastol
disord
pressur
control
antidiuret
treatment
start
heart
failur
prostanoid
analogu
effect
treat
lung
hypertens
epoprostenol
administr
reduc
lung
arteri
pressur
lung
vascular
resist
well
increas
cardiac
output
patient
sickl
cell
anemia
lung
hypertens
howev
chronic
treatment
patient
report
adolesc
sickl
cell
anemia
lung
hypertens
resist
sildenafil
bosentan
treprostinil
continu
sever
symptom
underw
bilater
lung
transplant
success
followup
